AroCell publishes the Annual Report for 2022

AroCell hereby announces that the annual report for 2022 has been published and is available on the company’s website: www.arocell.com.

The annual report is available at the following link: www.arocell.com/investors/financial-reports/

The report is available in Swedish only.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com